- Home
- INM vs SBFM Comparison
INM vs SBFM Comparison
Compare INM & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SBFM
- Stock Information
- Founded
- INM 1981
- SBFM 2006
- Country
- INM Canada
- SBFM United States
- Employees
- INM N/A
- SBFM N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- SBFM Health Care
- Exchange
- INM Nasdaq
- SBFM Nasdaq
- Market Cap
- INM 3.4M
- SBFM 3.7M
- IPO Year
- INM N/A
- SBFM N/A
- Fundamental
- Price
- INM $4.95
- SBFM $2.90
- Analyst Decision
- INM
- SBFM Strong Buy
- Analyst Count
- INM 0
- SBFM 1
- Target Price
- INM N/A
- SBFM $15.00
- AVG Volume (30 Days)
- INM 26.6K
- SBFM 151.9K
- Earning Date
- INM 02-11-2025
- SBFM 11-05-2024
- Dividend Yield
- INM N/A
- SBFM N/A
- EPS Growth
- INM N/A
- SBFM N/A
- EPS
- INM N/A
- SBFM N/A
- Revenue
- INM $4,960,506.00
- SBFM $32,959,491.00
- Revenue This Year
- INM N/A
- SBFM $59.94
- Revenue Next Year
- INM N/A
- SBFM $164.69
- P/E Ratio
- INM N/A
- SBFM N/A
- Revenue Growth
- INM 5.17
- SBFM 61.94
- 52 Week Low
- INM $2.42
- SBFM $2.11
- 52 Week High
- INM $15.70
- SBFM $572.00
- Technical
- Relative Strength Index (RSI)
- INM 55.90
- SBFM 49.22
- Support Level
- INM $4.07
- SBFM $2.79
- Resistance Level
- INM $5.41
- SBFM $2.94
- Average True Range (ATR)
- INM 0.39
- SBFM 0.26
- MACD
- INM 0.01
- SBFM -0.03
- Stochastic Oscillator
- INM 67.83
- SBFM 16.70
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.